ABSTRACT
Allergy is now acknowledged as one form of immunopathology, and the authors propose a protocol of comprehensive immunological examinations for the diagnosis of allergic diseases. This protocol includes the methods of examination and interpretation of the results, permitting the physician detect the predominant mechanism of allergic reaction (reagin, immunocomplex, or cytotoxic) determining the scientifically-based approach to selection of immune therapy.
Subject(s)
Hypersensitivity/immunology , Humans , Hypersensitivity/diagnosis , Immunologic TestsABSTRACT
Analysis of immunograms of 189 children with allergic diseases of the reagin type (55 with atopic bronchial asthma, 33 with atopic dermatitis, 101 with respiratory allergosis) helped single out a complex of immunological parameters which markedly and statistically reliably change in this type of allergy in comparison with a group of healthy children (n = 25). This complex is recommended to be used for the detection of the principal pathogenetic factor of the reagin-type allergic diseases and monitoring the therapy efficacy.
Subject(s)
Hypersensitivity/diagnosis , Adolescent , Antibody Formation , Asthma/diagnosis , Asthma/immunology , Child , Child, Preschool , Dermatitis, Atopic/diagnosis , Dermatitis, Atopic/immunology , Diagnosis, Differential , Humans , Hypersensitivity/immunology , Immunity, Cellular , Immunoglobulin E/blood , Immunologic Tests/methods , Respiratory Hypersensitivity/diagnosis , Respiratory Hypersensitivity/immunology , Rosette FormationABSTRACT
The diagnostic informative value of measurements of neuron-specific enolase (NSE) in health, pulmonary cancer (including small-cell one), 8 different diseases, and pregnant patients with gestation periods from 5 to 33 weeks was assessed. Comparison of the results in each of these 10 groups with the results in health controls did not reveal any appreciable differences for any of the groups or between the tested groups. The authors consider that NSE measurements cannot be recommended for use at other than cancer institutions.